Skip to content
MenuOpen navigation menu

Real moms, real GLP-1 talk

GLP-1s and Thyroid Medication: Two Different Questions

The thyroid-cancer warning differs from levothyroxine monitoring. What labels, a cohort and a case report support discussing with your clinician.

Written by — editorial research, not medical advice
On this page

Two thyroid questions worth separating

For someone taking levothyroxine, I would separate two thyroid questions before starting a GLP-1: the boxed warning about particular thyroid cancers, and the practical question of whether thyroid-hormone treatment needs monitoring. They are related to the same organ, but they are not the same reason for a prescribing decision.

I would bring my diagnosis, medicine and dose. A broad question about “thyroid disease” needs clarification; ordinary hypothyroidism is not the cancer history named in the warning.

Question one: the boxed warning

Every one of these drugs carries the same warning at the top of its label, in a box — the strongest form the FDA uses.

Zepbound's says that in rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures; that it is unknown whether Zepbound causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent finding has not been determined1. Wegovy's is the same shape, with semaglutide and "in rodents" in place of rats2.

Both are contraindicated if you or a family member has had medullary thyroid carcinoma, or if you have multiple endocrine neoplasia syndrome type 21,2 — that is what the intake form screens for. The symptoms both labels say to know are a lump in the neck, trouble swallowing, shortness of breath and hoarseness that will not go away1.

Neither softer nor harder than written, then: a rodent finding, human relevance stated as not determined, an absolute contraindication for those two histories — and both labels saying routine calcitonin monitoring and thyroid ultrasound are of uncertain value for catching MTC early1,2. The answer to being worried is not more screening, which is not what I expected.

And it is medullary thyroid carcinoma and MEN 2, not "thyroid disease". Ordinary hypothyroidism, Hashimoto's, levothyroxine treatment: none of it appears there.

Human data exist and are reassuring rather than conclusive. A Scandinavian cohort followed 145,410 people who started a GLP-1 against 291,667 who started a DPP-4 inhibitor: 76 thyroid cancers versus 184, a hazard ratio of 0.93 with a confidence interval of 0.66 to 1.31, over a mean 3.9 years3. The authors' own framing is the one I trust — the upper limit is consistent with no more than a 31% increase in relative risk. For medullary thyroid cancer the interval was too wide to say anything: 0.37 to 3.863.

Question two: levothyroxine and the formulation

The interaction question depends partly on the formulation. I would distinguish a semaglutide tablet from a weekly injection and ask how my other morning medicines fit the plan, rather than assume that slower gastric emptying always means lower absorption. The documented effect turned out to run the other direction, and narrower than I thought: Wegovy's label reports a drug-interaction study using the semaglutide tablet in which levothyroxine exposure went up by 33%, not down — and says that in the trials of the 1 mg once-weekly injection, semaglutide did not affect the absorption of orally administered medicines at all2.

Zepbound's label does not name levothyroxine anywhere; I looked. It carries a general caution that delayed gastric emptying may affect absorption of oral medications, and says to monitor anyone on a drug with a narrow therapeutic index — its example is warfarin1. Levothyroxine has a narrow index too, so I would ask about monitoring rather than assume the tablet interaction result describes every injection regimen.

Weight change and thyroid-hormone requirements

Changes in body weight can also change the amount of thyroid hormone someone needs. I would want the follow-up plan to address that possibility separately from the absorption question.

Body weight can influence levothyroxine requirements. A previously appropriate dose may need reassessment after substantial weight change; it should not be recalculated or reduced without the treating clinician.

One published case made me sit up: a 52-year-old woman, post-thyroidectomy and stable on levothyroxine for years, started tirzepatide, lost 48 pounds over six months, and turned up dizzy, tachycardic, weak and confused with a markedly suppressed TSH and a high free T4 — significantly over-replaced, needing an urgent dose reduction4. One case report, not a rate, and she had no thyroid of her own to buffer anything. But the mechanism is not exotic.

Then the study that annoyed me. Researchers matched 5,370 Medicare patients on a stable levothyroxine dose and compared starting a GLP-1 against starting an SGLT-2 inhibitor. About 83% of both groups had a TSH test within the year, at a mean of roughly 130 days — identical5. The drug that causes substantial weight loss made nobody check the thyroid dose sooner. That was an older group with type 2 diabetes, not moms in their thirties, and it still tells me the recheck is not automatic.

What I would ask, and when to call

I would ask when thyroid function should be checked, which symptoms should trigger an earlier call and who will interpret the results, since some of them overlap with other women’s GLP-1 side effects and with changes in nutrition. I would also ask how to take the medicines consistently rather than move the levothyroxine schedule on my own.

Do not wait for a scheduled recheck if you get a racing heart, a tremor, feeling hot when nobody else is, real insomnia, or anxiety that feels chemical rather than earned. Those are over-replacement symptoms, and on this drug they are easy to write off as the medication or as ordinary tiredness. And call about a new lump in your neck, hoarseness that does not clear, or trouble swallowing — that is the boxed-warning list, and it is not a wait-and-see.

Leave with both questions answered

I would want the clinician to address both questions explicitly: does my history meet a contraindication, and what monitoring does my thyroid treatment need as weight or symptoms change? A reassuring answer to the first does not make the second disappear.

I would leave with a monitoring plan and contact route for symptoms, rather than assume an unchanged thyroid prescription remains appropriate indefinitely.

Frequently asked questions

Can I take a GLP-1 if I have hypothyroidism or Hashimoto's?

The contraindication on these labels is a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2 — not thyroid disease generally. Ordinary hypothyroidism and Hashimoto's are not listed. That is a question for your prescriber, but it is a different question from the boxed warning.

Does a GLP-1 stop my levothyroxine from absorbing?

The formulation matters. A semaglutide-tablet interaction study reported 33% higher levothyroxine exposure. That result does not describe every injection regimen. Discuss timing and clinical or laboratory monitoring with the prescriber.

Do I need my thyroid dose changed if I lose weight on a GLP-1?

Possibly. Weight change can alter levothyroxine requirements, but the dose should be reassessed by the treating clinician rather than changed on your own. Discuss when to check thyroid function and which symptoms warrant earlier contact.

What does the thyroid boxed warning actually say?

That in rodents these drugs cause dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and that it is unknown whether they do so in humans because the human relevance of the rodent finding has not been determined. They are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. The labels also state that routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection.

References

  1. Eli Lilly and Company (2026). ZEPBOUND (tirzepatide) injection, for subcutaneous use — full prescribing information (boxed warning: risk of thyroid C-cell tumors; contraindications; drug interactions §7.2). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
  2. Novo Nordisk (2026). WEGOVY (semaglutide) injection and tablet — full prescribing information (boxed warning: risk of thyroid C-cell tumors; drug interactions §7.2, levothyroxine). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  3. Pasternak B, Wintzell V, Hviid A, et al. (2024). Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ. https://doi.org/10.1136/bmj-2023-078225
  4. Adams EW, Somers A, Garrido-Cortes E, Wrights B. (2026). Thyroid Dysfunction Following Tirzepatide Use in a Post-thyroidectomy Patient on Stable Levothyroxine Therapy: A Case Study. Cureus. https://doi.org/10.7759/cureus.106680
  5. Chen Y, Du F, Singh Ospina NM, et al. (2026). Patterns of Thyroid-Stimulating Hormone Test After GLP-1 RAs Initiation in Patients on Levothyroxine: A Trial Emulation Study. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag131

One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. Pregnancy planning and breastfeeding need advice for the exact medicine and formulation. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.